All Drug-Eluting Stents Are Not Created Equal

According to a meta-analysis, the everolimus-eluting stent is best at minimizing risk for stent thrombosis.

Concerns about stent thrombosis, particularly after discontinuation of dual antiplatelet therapy, have limited the use of drug-eluting stents (DESs). To compare the risk for stent thrombosis of second-generation everolimus-eluting stents (EESs) with those of other DESs, investigators conducted a meta-analysis of 13 randomized trials including 17,101 patients. In all studies, dual antiplatelet therapy was administered for 6 to 12 months after stent implantation.

EESs were compared with sirolimus-eluting stents (SESs) in eight trials, paclitaxel-eluting stents (PESs) in four trials, and zotarolimus-eluting stents (ZESs) in one trial. Weighted mean follow-up time was 21.7 months. Academic research consortium-defined definite or probable stent t…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI